Drainage Of Symptomatic Pancreatic Pseudocysts Research Articles

Endoscopic ultrasound-guided drainage of peripancreatic fluid collections: What impacts treatment duration?

BackgroundPeripancreatic fluid collections (PFCs) are complications resulting from acute or chronic pancreatitis and require treatment in certain clinical conditions. The present study aimed to identify the factors influencing the duration of endoscopic ultrasound (EUS)-guided drainage of symptomatic pancreatic pseudocysts (PPCs), walled-off necrosis (WON), and acute necrotic collections (ANCs). MethodsThis was a retrospective cohort study of 68 patients with PFCs who underwent EUS-guided drainage. The timing and duration of EUS-guided drainage of various PFCs (ANC, WON, and PPCs) were compared, and the factors influencing the duration of endoscopic treatment were identified. ResultsThe mean time to first EUS-guided PFC drainage since the acute pancreatitis episode was 372.0, 505.0, and 18.7 days for WON, PPC, and ANC, respectively, and the mean duration of treatment was 90, 60, and 63 days, respectively. A disconnected pancreatic duct, a history of percutaneous drainage, and an infected PFC were identified as factors influencing the treatment duration. A positive correlation was observed between the treatment duration and patients’ age. Patients with a disconnected pancreatic duct had to undergo more procedures. In patients with PPC, clinically successful drainage was more frequently achieved after a single procedure without the need for repeated procedures than in those with WON (90% vs. 59%, P = 0.01). ConclusionsPatients with a history of percutaneous drainage, disconnected pancreatic duct, or PFC infection may require longer endoscopic treatment.

Adverse events associated with AXIOS stents: Insights from the manufacturer and user facility device experience database.

ABSTRACTBackground and Objectives:The AXIOS stent is indicated for transgastric or transduodenal drainage of symptomatic pancreatic pseudocysts and symptomatic walled off necrosis. The AXIOS stent functions as a conduit which allows solid and liquid pancreatic fluid collections (PFC) contents to pass into the luminal GI tract and also allows the passage of standard and therapeutic endoscopes into the PFC to perform endoscopic debridement. We aim to investigate the number and type of complications associated with AXIOS stents.Materials and Methods:We analyzed postmarketing surveillance data from the Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE) database January 2016 to February 2021.Results:During the study period, approximately 588 reports with 579 device issues and 250 patient complications were identified. Most device complications were due to stent positioning problems or stent malpositioning (n = 206; 35.6%), followed by stent migration (n = 72; 12.4%), premature deployment (n = 61; 10.5%), material integrity (n = 56; 9.6%), deployment failure (n = 47; 8.1%), and difficulty removing the stent (n = 45; 7.7%). The most reported patient adverse events were hemorrhage/bleeding (n = 81; 32.4%), perforation (n = 26; 10.4%), pain (n = 22; 8.8%), unspecified infection (n = 20; 8.0%), and death (n = 17; 6.8%).Conclusions:Findings from the MAUDE database highlight patient and device complications which endoscopists should be aware of before AXIOS stent placement.

Safety and Feasibility of Robotic-Assisted Drainage of Symptomatic Pancreatic Pseudocysts: A Case-Series Analysis (with video).

Background: The surgical treatment of pancreatic pseudocysts (PPs) in patients who fail nonoperative management has evolved from aggressive open to a minimally invasive approach. The application of robotic surgery in this setting is scarcely reported. The aim of this study is to analyze the safety and feasibility of the robotic approach to pancreatic pseudocyst drainage. Methods: A single centre retrospective review of consecutive patients undergoing robotic-assisted pancreatic pseudocyst surgeries in an academic tertiary institution was performed. Results: There were 14 patients studied, of whom 10 underwent cystogastrostomy and 4 Roux-En- Y cystojejunostomy. Eight patients had gallstone pancreatitis and 3 patients alcoholic pancreatitis. The mean size of cyst was 8.9 +-1cm and 57.1% located at the pancreatic body. The overall operative time of the procedure was 135 +-34 minutes. There were no open conversions. The overall success rate was 92.8%, while the primary success rate 85.7%. The major morbidity rate was 14.3% and there was no 30-day mortality. The mean post-operative hospital stay was 7 +-3 days with one recurrence of the pancreatic pseudocyst on follow-up requiring endoscopic drainage without further recurrence. Conclusions: The robotic approach for the drainage of symptomatic pancreatic pseudocyst is safe and feasible and can be considered as a viable modality for operative intervention in well-selected patients.

Endoscopic Ultrasound-Guided Pancreatic Pseudocyst Drainage in Children

Background: Endoscopic drainage of pancreatic pseudocysts is well established in adults and known to be associated with complications including perforation and hemorrhage. One reason for this is that endoscopic drainage is a blind procedure and to overcome this, EUS guided drainage was established. However, there are limited data regarding this procedure in the pediatric age group. The reasons for this are the limited number of cases seen in children and the lack of experienced pediatric gastroenterologist with this technique. Add to this another technical limitation with EUS is that the therapeutic echo endoscope is 14.6 mm in diameter and has a rigid tip that restricts its use in young children. Patients, methods and results: This report describes a 4-year old child weighing 14 kg with a large pancreatic pseudocyst (8x8x12cm) that was treated successfully using adult endoscopic ultrasound scope (The Olympus EVIS LUCERA Ultrasound Gastrovideoscope GF-UCT 260, 14.6 mm distal tip). Conclusion: Endoscopic drainage of symptomatic pancreatic pseudocysts can be achieved safely and effectively in children using the adult EUS scope.

Efficacy, Safety, and Long-Term Follow-Up Results of EUS-Guided Transmural Drainage for Pancreatic Pseudocyst

Background and Aim. EUS-guided transmural drainage (EUS-GTD) is now considered a minimally invasive and effective alternative to surgery for drainage of symptomatic pancreatic pseudocysts. However, the technique is rather difficult, and sometimes serious complications occur to patients undergoing this procedure. We retrospectively evaluated efficacy, safety, and long-term follow-up results of EUS-GTD for pancreatic pseudocyst. Methods. Sixty-seven patients with pancreatic pseudocyst who underwent EUS-GTD from April 2000 to March 2011 were enrolled. We retrospectively evaluated (1) technical success, (2) clinical success, (3) adverse event of procedure, and (4) long-term follow-up results. Results. Total technical success rate was 88%. Ninety-one percent of external drainage, 79% of internal drainage, and 66% of puncture and aspiration only achieved clinical success. There was only one case with an adverse event, perforation (1.5%). The case required emergency operation. Total recurrence rate was 23.9%. Median follow-up period was 33.9 months. The recurrence rates in the cases of stent remaining, spontaneously dislodged, removed on schedule, external tube removal, and aspiration only were 10.0%, 12.5%, 42.9%, 50%, and 0%, respectively. Conclusion. EUS-GTD is a relatively safe and effective therapeutic method. However, further analysis should be done by larger series to determine the method of EUS-GTD for pancreatic pseudocyst.

Efficacy of Endoscopic Ultrasound-Guided Drainage of Pancreatic Pseudocysts in a Pediatric Population

While pancreatitis is uncommon in children, pseudocyst development can be a serious complication. Endoscopic drainage of pseudocysts is well established in adults. However, there are limited data regarding this procedure in a pediatric population. The objective of this study is to determine the safety and efficacy of endoscopic ultrasound-guided pseudocyst drainage in children. The study group included children (age <18 years) who presented for endoscopic drainage of symptomatic pancreatic pseudocysts in whom endoscopic ultrasound (EUS) was performed. In those cases with EUS guidance, a 19-gauge needle was used to access the pseudocyst and place a guidewire under fluoroscopic visualization. Needle-knife diathermy and balloon dilation of the tract were performed with subsequent placement of double pig-tailed stents for drainage. Ten children with mean age of 11.8 years (range 4-17 years) were analyzed for pancreatic pseudocysts due to biliary pancreatitis (n = 4), trauma (n = 2), familial pancreatitis (n = 1), idiopathic pancreatitis (n = 2), and pancreas divisum (n = 1). In eight cases, EUS-guided puncture and stent placement was successful. In the remaining two cases, aspiration of cyst fluid until complete collapse was adequate. As experience increased with EUS examination in children, the therapeutic EUS scope alone was used in 50% of cases for the entire procedure. In all ten cases, successful transgastric endoscopic drainage of pseudocysts was achieved. Endoscopic drainage of symptomatic pancreatic pseudocysts can be achieved safely in children. EUS guidance facilitates optimal site of puncture as well as placement of transmural stents.

Temporary cystogastrostomy with self-expanding metallic stents for pancreatic necrosis

Conventional endoscopic drainage of symptomatic pancreatic pseudocysts has its limitations when the content of the collection is nonfluid. This leads to obstruction of placed flap stents; it requires the placement of an irrigation catheter and repeated implantation of several stents. Herein we describe the temporary use of a special self-expanding partially covered metal mesh stent, which was designed to keep the pancreaticogastrostomy open for drainage of walled-off necrosis and for further endoscopic necrosectomies. The stent has a diameter of 20-25 mm and a length of 50 mm and was placed following the first transgastric removal of necrotic masses. After a treatment period of 7-11 days involving 2-3 endoscopic procedures we achieved clinical success, defined as complete removal of necrotic masses, in all cases without major complications.

3502 A new device for endoscopic, transmural, drainage of symptomatic pancreatic pseudocysts.

Endoscopic transmural drainage of a pancreatic pseudocyst is a technically demanding procedure. An instrument that allows easy cyst puncture and catheter drainage is much needed. Methods: to design a drainage device that allows endoscopic pseudocyst puncture and passage of a large bore drain in a single step. This device must have the following functions: 1) allow rapid insertion of a 10 French double pigtail stent; 2) retrieve or adjust the stent during a deployment attempt without losing pseuodcyst access or having to remove the endoscope; 3) confirm pseudocyst access by contrast injection; 4) re-loadable for placement of additional drains. We have designed a device that has a central diathermy needle at its tip, a stent pusher, and a double pig-tail stent that is held in place by a cable. Results: Five of 6 patients have been successfully treated with this device. However, several technical problems were encountered initially. In the first patient, the cable broke before stent deployment. In the second and third patients, an assistant had to manually hold on to the cable to secure the stent. The cable had to be cut for stent release, and stent re-loading was time consuming. Endoscopic pseudocyst puncture failed in the fourth patient, due to difficulty in establishing access. Additonally, cable breakage necessitated endoscope removal from this patient. After multiple device modifications that included using a stronger cable and a self-locking mechanism, the last 2 patient had four stent placements without any difficulty. The time needed for cyst puncture, contrast injection, and stent insertion and release range from 1-5 minutes. Stent re-loading was accomplished rapidly. In total, 7 drains have been successfully placed with this device without any complications directly related to it. Conclusions: a new, singlestep endoscopic pseudocyst drainage device has been created, negating time-consuming, complicated procedures that may involve guidewire exchange and transmural dilation. Loss of endoscopic visualization and pseudocyst access may be prevented with the use of this device. A larger clincal experience is needed to confirm its values.